Conflicts of interest:
Prevention of polymorphic light eruption by oral administration of a nutritional supplement containing lycopene, β-carotene, and Lactobacillus johnsonii: results from a randomized, placebo-controlled, double-blinded study
Article first published online: 2 JAN 2014
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Photodermatology, Photoimmunology & Photomedicine
Volume 30, Issue 4, pages 189–194, August 2014
How to Cite
Marini, A., Jaenicke, T., Grether-Beck, S., Le Floc'h, C., Cheniti, A., Piccardi, N. and Krutmann, J. (2014), Prevention of polymorphic light eruption by oral administration of a nutritional supplement containing lycopene, β-carotene, and Lactobacillus johnsonii: results from a randomized, placebo-controlled, double-blinded study. Photodermatology, Photoimmunology & Photomedicine, 30: 189–194. doi: 10.1111/phpp.12093
This study has been supported by Laboratoires Inneov, Asnières sur Seine, France.
- Issue published online: 22 JUL 2014
- Article first published online: 2 JAN 2014
- Accepted manuscript online: 28 NOV 2013 02:44AM EST
- Manuscript Accepted: 21 NOV 2013
- Laboratoires Inneov, Asnières sur Seine, France
- polymorphic light eruption;
- systemic photoprotection
Polymorphic light eruption (PLE) is the most common photodermatosis. Little is known about the efficacy of systemic photoprotection provided by nutritional supplements in PLE patients.
The purpose of this study was to assess efficacy of nutritional supplement containing lycopene, β-carotene, and Lactobacillus johnsonii to diminish skin lesions induced by ‘photoprovocation’ testing in PLE patients.
In this randomized, placebo-controlled, double-blinded study, 60 PLE patients were supplemented with the nutritional supplement or placebo. For inducing skin lesions, patient skin was exposed to single daily doses of 100 J/cm2 ultraviolet A1 (UVA1) for two consecutive days. Skin lesions were evaluated using a PLE score. Skin biopsies were taken before and after supplementation from unexposed and exposed skin, and intercellular adhesion molecule 1 (ICAM-1) mRNA expression was assessed by real-time polymerase chain reaction.
Prior to supplementation, skin lesions were induced in all patients with comparable PLE scores. After 12 weeks, intake of the supplement significantly reduced the PLE score after one exposure as compared with patients taking placebo (P < 0.001). After two exposures, these differences were no longer significant. At a molecular level, the development of skin lesions was associated with an increased expression of ICAM-1 mRNA, which was significantly reduced after supplementation (P = 0.022), but not with placebo.
The nutritional supplement provides protection against the development of UVA-induced PLE lesions at clinical and molecular levels.